Rexinoids may be ready for prime time in prevention, but challenges remain.
Hede
Karyn
K
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D000077610:Bexarotene; D001943:Breast Neoplasms / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D009539:Nicotinic Acids / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D047488:Retinoid X Receptors / Q000187:drug effects* / Q000378:metabolism*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology
D016588:Anticarcinogenic Agents; D009539:Nicotinic Acids; D010880:Piperidines; D047488:Retinoid X Receptors; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; D000077610:Bexarotene; C115121:LY 353381; C095104:LG 100268